Trimethylazanium;hydroxide | 15875-97-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Trimethylazanium;hydroxide
• CAS: 15875-97-5
• 化学式: C3H11NO
• 分子量: 77.13
• InChiKey: BJAARRARQJZURR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.65
• 重原子数：
  5
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  4.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  环氧乙烷 、 Trimethylazanium;hydroxide 、 三甲胺 以 甲醇 为溶剂， 生成 胆碱 、 聚合甲醛
  参考文献：
  名称：

  Stabilized choline base solutions

  摘要：

  胆碱基，(2-羟基乙基)三甲基氢氧化铵在水和/或低碳醇中的溶液可以通过添加稳定浓度的甲醛或多聚甲醛来稳定。 稳定的溶液可用作清洁溶液，半导体和金属层的蚀刻剂，以及用于正向光刻胶的显影剂和去除剂，以及其他需要无金属离子基础的用途。

  公开号：

  US04686002A1

文献信息

• METHOD FOR MANUFACTURING A NANOPOROUS FRAMEWORK AND A NANOPOROUS FRAMEWORK THUS PRODUCED
  申请人：Garcia-Bennet Alfonso E.

  公开号：US20090060830A1

  公开（公告）日：2009-03-05

  The invention concerns a method for manufacturing nanoporous metal oxide or metal active sites frameworks in which the metal oxide precursor is distributed into the framework in the form of a metal soap surfactant. The invention also covers a nanostructure framework comprising metal oxide active sites which are evenly distributed in the framework.

  本发明涉及一种制造纳米多孔金属氧化物或金属活性位框架的方法，其中金属氧化物前体以金属肥皂表面活性剂的形式分布在框架中。本发明还涵盖一种纳米结构框架，其中金属氧化物活性位均匀分布在框架中。
• Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
  申请人：Traquandi Gabriella

  公开号：US20070185143A1

  公开（公告）日：2007-08-09

  Pyrazolo-quinazoline derivatives of formula (Ia) or (Ib) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention maybe useful in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer”.

  本发明公开了公式（Ia）或（Ib）中定义的吡唑并[3,4-d]喹唑啉衍生物及其药学上可接受的盐，其制备方法和包含它们的制药组合物；本发明中的化合物可能在治疗中有用，用于治疗与蛋白激酶活性失调有关的疾病，如癌症。
• Method for manufacturing a nanoporous framework and a nanoporous framework thus produced
  申请人：Nanologica AB

  公开号：US08075867B2

  公开（公告）日：2011-12-13

  The invention concerns a method for manufacturing nanoporous metal oxide or metal active sites frameworks in which the metal oxide precursor is distributed into the framework in the form of a metal soap surfactant. The invention also covers a nanostructure framework comprising metal oxide active sites which are evenly distributed in the framework.

  该发明涉及一种制造纳米多孔金属氧化物或金属活性位点框架的方法，其中金属氧化物前体以金属皂表面活性剂的形式分布在框架中。该发明还涵盖了一种纳米结构框架，其中金属氧化物活性位点均匀分布在框架中。
• PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS
  申请人：Traquandi Gabriella

  公开号：US20130338148A1

  公开（公告）日：2013-12-19

  Pyrazolo-quinazoline derivatives of formula (Ia) or (Ib) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

  本发明揭示了式(Ia)或(Ib)的吡唑并喹唑啉衍生物及其药学上可接受的盐，以及它们的制备方法和包含它们的制药组合物；本发明的化合物可能在治疗与蛋白激酶活性失调相关的疾病，如癌症方面有用。
• Pyrazolo quinazoline derivatives, process for their preparation and their use as kinase inhibitors
  申请人：Traquandi Gabriella

  公开号：US08541429B2

  公开（公告）日：2013-09-24

  Pyrazolo-quinazoline derivatives of formula (Ia) or (Ib) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

  本发明公开了式(Ia)或(Ib)的吡唑喹唑啉衍生物及其药学上可接受的盐，以及其制备方法和包含它们的药物组合物；本发明的化合物可能在治疗与蛋白激酶活性失调相关的疾病，如癌症方面有用。